Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Daniela, Saggioro"'
Autor:
Elisa Boldrin, Matteo Curtarello, Matteo Fassan, Massimo Rugge, Stefano Realdon, Rita Alfieri, Alberto Amadori, Daniela Saggioro
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Esophageal cancer (EC) is a highly aggressive tumor, and the current monitoring procedures are partially inadequate to evaluate treatment efficacy. The aim of this study was to investigate whether allelic imbalance analysis in liquid biopsy could be
Externí odkaz:
https://doaj.org/article/b70a3637e0d84c41aa98ac86e229ff5d
Autor:
Elisa Boldrin, Sandro Malacrida, Enrica Rumiato, Giorgio Battaglia, Alberto Ruol, Alberto Amadori, Daniela Saggioro
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Esophageal cancer (EC) is a very aggressive tumor, and no reliable prognostic markers exist especially for resectable advanced neoplasia. The principal aim of this study was to investigate the association of germline polymorphisms in nucleotide excis
Externí odkaz:
https://doaj.org/article/51553e6d6c0c4f368a46dcf311873d02
Autor:
Daniela Saggioro
Publikováno v:
Viruses, Vol 3, Iss 7, Pp 1001-1014 (2011)
The NF-κB pathway is intimately linked to the survival of mammalian cells, and its activation by Tax has consequently been considered important for human T-cell leukemia/lymphoma virus type 1 (HTLV-1)-infected cell resistance to death. Very little e
Externí odkaz:
https://doaj.org/article/ea2de5006cd541669f1ab93da4b18542
Autor:
Elisa Boldrin, Enrica Rumiato, Matteo Fassan, Rocco Cappellesso, Massimo Rugge, Vanna Chiarion-Sileni, Alberto Ruol, Rita Alfieri, Matteo Cagol, Carlo Castoro, Alberto Amadori, Daniela Saggioro
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0117070 (2015)
BACKGROUND: Development of novel therapeutic drugs and regimens for cancer treatment has led to improvements in patient long-term survival. This success has, however, been accompanied by the increased occurrence of second primary cancers. Indeed, pat
Externí odkaz:
https://doaj.org/article/c3cbc60a55d44dca86eb50e5a96a87c0
Autor:
Enrica Rumiato, Alberto Ruol, Daniela Saggioro, Sandro Malacrida, Vanna Chiarion Sileni, Alberto Amadori, Elisa Boldrin, Giorgio Battaglia
Publikováno v:
Pharmacogenomics. 21(6)
Aim: Clinical features of esophageal cancer (EC) patients have poor prognostic power. Thus, it is paramount to discover biomarkers that can allow a more accurate survival prediction. Methods: To detect genetic variants associated with survival, DNA f
Autor:
Stefano Indraccolo, Giorgia Nardo, Laura Bonanno, Daniela Saggioro, Valentina Polo, Alberto Pavan, Stefano Frega, Elisabetta Zulato, Elisa Boldrin
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 1
Volume 21
Issue 1
Liquid biopsy is currently approved for management of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients. However, one unanswered question is whether the rate of cell-free DNA (cfDNA)-negative samples is due t
Autor:
Elisa, Boldrin, Sandro, Malacrida, Enrica, Rumiato, Giorgio, Battaglia, Alberto, Ruol, Alberto, Amadori, Daniela, Saggioro
Publikováno v:
Frontiers in Oncology
Esophageal cancer (EC) is a very aggressive tumor, and no reliable prognostic markers exist especially for resectable advanced neoplasia. The principal aim of this study was to investigate the association of germline polymorphisms in nucleotide excis
Autor:
F Pasini, Selma Ahcene-Djaballah, Daniela Menon, Lucia Borgato, Milena Gusella, Alberto Amadori, Enrica Rumiato, Daniela Saggioro, Antonella Brunello, Vittorina Zagonel
Publikováno v:
Europe PubMed Central
So far, no reliable predictive clinicopathological markers of response to aromatase inhibitors (AIs) have been identified, and little is known regarding the role played by host genetics. To identify constitutive predictive markers, an array-based ass
Autor:
Enrica Rumiato, Alberto Amadori, Elisa Boldrin, Sandro Malacrida, Daniela Saggioro, Giorgio Battaglia, Massimo Rugge, T. Morbin, Matteo Fassan, Stefano Realdon
Barrett's esophagus (BE) is associated with an increased risk of developing esophageal adenocarcinoma. Despite the low absolute risk of neoplastic progression of BE, probability increases with the diagnosis of dysplasia. For this reason, BE patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4824de7b68e42b8d91af75c05c1a2303
http://hdl.handle.net/11577/3251496
http://hdl.handle.net/11577/3251496
Chemoradiotherapy followed by surgery is at present the standard therapeutic approach for esophageal cancer (EC) in patients with resectable tumor. However, response to neoadjuvant therapy is characterized by a strong interpatient variability, and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::535f549fe0fef070e1191a38b8cc6694
http://hdl.handle.net/11577/3195344
http://hdl.handle.net/11577/3195344